Efficacy of propafenone for maintaining sinus rhythm in patients with recent onset or persistent atrial fibrillation after conversion: A randomized, placebo-controlled study

Acta Cardiologica

Volumn 59, Issue 3, 2004, Pages 255-261

  Dogan, Abdullah ^a,b   Ergene, Oktay ^a   Nazli, Cem ^a   Kinay, Ozan ^a   Altinbas, Ahmet ^a   Ucarci, Yesim ^a   Ergene, Ulku ^a   Ozaydin, Mehmet ^a   Gedikli, Omer ^a  

^a SULEYMAN DEMIREL UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

Atrial fibrillation; Propafenone; Sinus rhythm

Indexed keywords

PLACEBO; PROPAFENONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HUMAN; KAPLAN MEIER METHOD; LUNG DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; SINUS RHYTHM;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA, SINUS; ATRIAL FIBRILLATION; CHRONIC DISEASE; ELECTRIC COUNTERSHOCK; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLACEBOS; PROPAFENONE; RECURRENCE; TIME FACTORS;

EID: 2942711561     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.59.3.2005179     Document Type: Article

References (22)

1. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalance, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med 1995; 155: 469-73.
2. Prystowsky EN, Benson DW, Fuster V, Hart RG, Kay GN, Myerburg RJ, Naccarelli GW, Wyse DG. Management of patients with atrial fibrillation: a statement for healthcare professionals from the committee on Electrocardiography and Electrophysiology American Heart Association. Circulation 1996; 93: 1262-77.
3. Braunwald E. Shattuck lecture - cardiovascular medicine at the turn of the millennium: triumphs, concerns, and oppurtunities. N Engl J Med 1997; 337: 1360-9.
4. Fuster V, Ryden LE, Asinger RW, Cannon DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC, Klein WW, Alonso-Garcia A, Blomstorm-Lundqvist C, De Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A. ACC/AHA/ESC Guidelines for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society Cardiology Committee for Practice Guidelines and Policy Conferences developed in collaboration with the North American Society for Pacing and Electrophysiology. J Am Coll Cardiol 2001; 38: 1231-65.
5. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-33.
6. Van Gelder IC, Hagens VE, Bosker HA, Kingma H, Kamp O, Kingma T, Said SA, Darmanata JI, Timmermans AJM, Tijssen JGP, Crijns HJG. For the Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 347: 1834-40.
7. Van Gelder IC, Crijns HJ, Tieleman RG, Brugemann J, De Kam PJ, Gosselink AT, Verheugt FW, Lie KI. Chronic atrial fibrillation: success of serial cardioversion therapy and safety of oral anticoagulation. Ann Intern Med 1996; 156: 2585-92.
8. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: a meta-analysis of randomized controlled trials. Circulation 1990; 82; 1106-16.
9. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993; 71: 558-63.
10. Antman EM, Beamer AD, Cantillon C, McGowan N, Goldman L, Friedman PL. Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and flutter. J Am Coll Cardiol 1988; 12: 1005-11.
11. Gosselink AT, Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld AC, Lie KI. Low dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992; 262: 3289-20.
12. Roy D, Talajic M, Dorivan P, Connolly S, Eisenberg MJ, Green M, Kus T, Lambert J, Dubuc M, Gagne P, Nattel S, Thibault B. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000; 342: 913-20.
13. Kochiadakis GE, Marketou ME, Igoumenidis NE, Chrysostomakis SI, Mavrakis HE, Kaleboubas MD, Vardas PE. Amiodarone, sotalol, and propafenone in atrial fibrillation which is preferred to maintain normal sinus rhythm. Pacing Clin Electrophysiol 2000; 23: 1883-7.
14. Bellandi F, Simonetti I, Leoncini M, Frascarelli F, Giovannini T, Maioli M, Dabizzi RP. Long-term efficacy and safety of propafenone, sotalol for the maintenance of sinus rhythm after conversion of recurrent symptomatic atrial fibrillation. Am J Cardiol 2001; 88: 640-5.
15. Lee SH, Chen SA, Tai CT, Chiang CE, Wen ZC, Chen YC, Yu WC, Huang JL, Fong AN, Cheng JJ, Jhang MS. Comparisons of oral propafenone and sotalol as initial treatment in patients with symptomatic paroxysmal atrial fibrillation. Am J Cardiol 1997; 79: 905-8.
16. Lau CP, Moses SS, Tse HF, Tang MO, Fan C. Controls of paroxysmal atrial fibrillation recurrence using combined administration of propafenone and quinidine. Am J Cardiol 2000; 86: 1327-32.
17. Stroobandt R, Stiels B, Hoebrechts R. Propafenone Atrial Fibrillation Trial Investigators. Propafenone for conversion and prophylaxis of atrial fibrillation. Am J Cardiol 1997; 79: 418-23.
18. Reimold SC, Maisel WH, Antman EM. Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis. Am J Cardiol 1998; 82: 66N-71N.
19. Ergene U, Ergene O, Cete O, Fowler J, Nazli C, Oktay C. Predictors of success in the conversion of new onset atrial fibrillation using oral propafenone. Eur J Emerg Med 1998; 5: 425-8.
20. Kannel WB, Abbot RD, Savage DD, McNamara PM. Epidemiologic features of chronic atrial fibrillation: The Framingham Study. N Engl J Med 1982; 3606: 1018-22.
21. Middlekauff HR, Stevenson WG, Stevenson LW. Prognostic significance of atrial fibrillation in advanced heart failure: a study of 390 patients. Circulation 1991; 84: 40-8.
22. Morillo CA, Klein GJ, Jones DL, Yee R. Chronic rapid atrial pacing: structural, functional and electrophysiological characteristics of a new model of sustained atrial fibrillation. Circulation 1995; 91: 1588-95.